pneumonia
major
global
health
problem
kill
children
year
age
diseas
burden
diseas
aggrav
old
age
chronic
lung
diseas
immunosuppress
viral
coinfect
secondari
pneumonia
follow
pandem
season
influenza
viru
infect
signific
caus
mortal
worldwid
nasopharyng
colon
streptococcu
pneumonia
spn
pneumococcu
common
infant
adult
colonis
time
pneumococc
carriag
import
prerequisit
infect
primari
reservoir
transmiss
predomin
sourc
immun
exposur
immunolog
boost
children
adult
immun
dysregul
caus
respiratori
viru
infect
influenza
lead
increas
carriag
load
increas
carriag
load
associ
pneumonia
incid
sever
well
withinhousehold
spn
transmiss
mechan
marker
associ
pathogen
synergi
difficult
studi
human
subject
due
rapid
natur
diseas
one
safe
way
simul
influenza
infect
nose
use
live
attenu
influenza
vaccin
laiv
consist
coldadapt
influenza
virus
laiv
shown
affect
subsequ
suscept
spn
lead
increas
carriag
load
murin
model
infect
vaccin
children
furthermor
laiv
administr
prior
spn
challeng
led
increas
spn
acquisit
molecular
method
well
increas
nasopharyng
bacteri
load
murin
model
pneumococc
carriag
recruit
neutrophil
monocyt
nasopharynx
mediat
immunolog
control
clearanc
influenza
viru
infect
promot
type
interferon
interfer
recruit
phagocyt
although
postul
impair
phagocytosi
macrophag
downregul
scaveng
receptor
marco
howev
precis
immun
mechan
gene
regul
involv
control
clearanc
pneumococc
carriag
human
reveal
moreov
mechan
alter
human
influenza
viru
infect
remain
larg
unknown
system
biolog
approach
allow
identif
immun
mechan
associ
protect
infecti
diseas
robust
immun
respons
vaccin
appli
system
biolog
nasal
sampl
collect
set
human
challeng
laiv
spn
emul
nasal
effect
influenza
infect
spn
carriag
identifi
first
time
human
key
cellular
mechan
control
newli
acquir
pneumococc
carriag
disrupt
follow
nasal
influenza
infect
doubleblind
control
random
clinic
trial
administ
laiv
three
day
prior
spn
inocul
day
verifi
requisit
topic
applic
effect
pneumococc
carriag
administ
tetraval
inactiv
influenza
vaccin
tiv
control
laiv
infect
led
transient
increas
pneumococc
acquisit
day
vs
molecular
method
laiv
vs
control
group
respect
laiv
also
increas
spn
carriag
load
first
day
follow
pneumococc
inocul
supplementari
fig
collect
seri
nasal
microbiopsi
nasal
line
fluid
throughout
studi
assess
ongo
cellular
cytokin
respons
particip
group
becom
colon
follow
spn
challeng
carriag
determin
classic
microbiolog
fig
investig
whether
laivinduc
immun
respons
associ
predisposit
pneumococc
carriag
measur
concentr
cytokin
protein
includ
nasal
line
fluid
fig
day
directli
prior
spn
inocul
laiv
significantli
increas
concentr
twenti
cytokin
multipl
test
correct
includ
tnf
fig
supplementari
tabl
contrast
control
group
show
signific
increas
cytokin
respons
day
follow
spn
inocul
spn
carriag
absenc
laiv
associ
increas
concentr
epiderm
growth
factor
egf
day
decreas
concentr
day
post
spn
inocul
compar
baselin
neither
remain
signific
multipl
test
correct
cytokin
includ
significantli
alter
carriag
alon
fig
even
bacteri
inocul
nasal
inflammatori
respons
laiv
differ
went
becom
carrier
protect
carriag
fig
particular
significantli
increas
laivvaccin
subject
acquir
spn
follow
inocul
increas
becam
carrier
follow
inocul
increas
contrast
significantli
increas
subject
went
becom
carrier
increas
remain
carriageneg
increas
moreov
subject
increas
concentr
inocul
display
higher
pneumococc
load
follow
spn
inocul
fig
suggest
differ
respons
influenza
viru
associ
secondari
suscept
spn
test
whether
specif
laiv
infect
measur
nasal
wash
independ
cohort
subset
subject
asymptomat
viral
upper
respiratori
tract
infect
week
spn
inocul
progress
symptomat
infect
compris
rhinoviru
coronaviru
respiratori
syncyti
viru
parainfluenzaviru
predomin
viru
rhinoviru
recent
shown
associ
increas
pneumococc
acquisit
transmiss
virusinfect
subject
concentr
increas
supplementari
fig
baselin
concentr
correl
increas
pneumococc
load
also
second
cohort
fig
unfortun
sampl
size
small
investig
depth
effect
infect
differ
virus
like
diverg
effect
although
correl
modest
valid
cohort
suggest
host
environment
factor
involv
first
time
biomark
predict
spn
load
identifi
murin
model
neutrophil
recruit
onset
carriag
contribut
control
bacteria
observ
preexist
high
number
neutrophil
human
nasal
line
pneumococc
carriag
lead
signific
recruit
neutrophil
supplementari
fig
b
investig
whether
lumin
neutrophil
involv
earli
control
carriag
measur
myeloperoxidas
mpo
concentr
marker
neutrophil
degranul
nasal
wash
concentr
increas
day
challeng
control
carriag
individu
fig
neutrophil
activ
impair
laiv
group
display
high
carriag
load
earli
carriag
increas
acquisit
compar
control
togeth
suggest
neutrophil
degranul
import
initi
control
carriag
investig
whether
neutrophil
also
impair
system
follow
laiv
report
wildtyp
influenza
infect
isol
blood
neutrophil
three
day
laiv
administr
subset
subject
confirm
opsonophagocyt
opk
kill
spn
blood
neutrophil
decreas
follow
laiv
fig
effect
could
mimick
addit
tnf
neutrophil
healthi
donor
vitro
decreas
kill
capac
dosedepend
manner
fig
nanostr
express
analysi
gene
reveal
differenti
express
gene
blood
neutrophil
day
post
laiv
supplementari
tabl
among
increas
act
tnf
signal
transduct
pathway
coinhibitori
receptor
tigit
increas
fig
tigit
express
level
also
neg
correl
neutrophil
kill
capac
fig
tigit
immun
checkpoint
protein
describ
promot
regulatori
cell
treg
cell
function
express
neutrophil
previous
appreci
incub
whole
blood
recombin
tnf
increas
tigit
level
neutrophil
surfac
within
minut
dosedepend
manner
fig
taken
togeth
inflamm
follow
laiv
impair
respons
nasal
system
neutrophil
pneumococcu
could
mimick
addit
exogen
tnf
neutrophil
associ
upregul
tigit
immunophenotyp
reveal
signific
recruit
monocyt
nose
follow
establish
carriag
fig
supplementari
fig
monocyt
number
increas
earli
day
follow
spn
inocul
peak
day
median
increas
remain
elev
day
post
spn
inocul
contrast
recruit
cell
nose
supplementari
fig
laiv
infect
prior
pneumococc
carriag
impair
recruit
monocyt
nose
fig
moreov
peak
pneumococc
load
associ
increas
monocyt
recruit
control
group
laiv
group
fig
c
inde
subject
control
group
low
carriag
densiti
detect
molecular
method
monocyt
recruit
observ
supplementari
fig
suggest
minimum
spn
load
requir
sens
monocyt
recruit
laiv
infect
interfer
process
although
substanti
induc
follow
spn
carriag
concentr
correl
number
monocyt
timepoint
supplementari
fig
furthermor
stratif
individu
show
increas
concentr
day
post
spn
inocul
exhibit
increas
monocyt
recruit
supplementari
fig
concentr
tnf
also
correl
number
monocyt
time
point
stratif
individu
reveal
differenti
recruit
monocyt
supplementari
fig
b
second
independ
cohort
receiv
vaccin
monocyt
increas
day
follow
spn
inocul
correl
increas
concentr
nasal
fluid
valid
result
supplementari
tabl
supplementari
fig
thu
acquisit
pneumococc
carriag
led
recruit
monocyt
nasopharynx
process
associ
pneumococc
load
induct
inhibit
laiv
infect
assess
antipneumococc
respons
induc
carriag
collect
nasal
cell
day
post
spn
inocul
stimul
vitro
heatkil
spn
measur
concentr
cytokin
supernat
increas
product
foldchang
fc
q
unstimul
control
tnf
gmcsf
upon
restimul
observ
control
carriag
group
fig
supplementari
fig
laiv
carriag
group
howev
boost
antipneumococc
cytokin
respons
rechalleng
absent
fig
supplementari
fig
product
five
cytokin
correl
decreas
pneumococc
load
day
post
spn
inocul
suggest
respons
involv
spn
clearanc
fig
test
whether
monocytesmacrophag
sourc
cytokin
compar
cytokin
signatur
whole
nasal
cell
alveolar
macrophag
expos
spn
vitro
fig
rel
cytokin
product
highli
correl
two
cell
popul
suggest
nasal
monocytesmacrophag
could
sourc
cytokin
support
observ
carrier
low
carriag
load
detect
molecular
method
absenc
monocyt
recruit
associ
absent
spnspecif
respons
supplementari
fig
conclus
carriag
led
increas
respons
nasal
cell
pneumococc
stimul
potenti
due
infiltr
monocyt
impair
prior
laiv
infect
correl
clearanc
pneumococc
carriag
supplementari
fig
identifi
gene
signatur
associ
observ
respons
pneumococc
carriag
infect
laiv
perform
rnasequenc
whole
nasal
cell
day
spn
inocul
fig
supplementari
tabl
carriag
without
laiv
induc
differenti
express
gene
deg
day
day
respect
fig
gene
enrich
pathway
associ
gap
junction
traffick
regul
includ
multipl
gjb
degrad
extracellular
matrix
includ
group
smaller
number
deg
observ
day
day
respect
laiv
carriag
group
deg
observ
day
day
respect
surprisingli
despit
high
concentr
inflammatori
cytokin
observ
laiv
group
rel
small
number
deg
observ
day
respect
deg
carriag
subject
receiv
laiv
deg
carriag
without
laiv
show
littl
overlap
deg
day
deg
day
common
littl
overlap
observ
pathway
level
group
indic
laiv
alter
natur
respons
pneumococcu
fig
supplementari
tabl
could
reflect
transcriptom
kinet
observ
alter
differenti
cellular
activ
chang
cell
migrat
nasal
mucosa
laiv
carriag
group
show
enrich
gene
tolllik
receptor
signal
cascad
mediat
induct
ifnalphabeta
pathway
ifngamma
signal
agreement
induct
antivir
respons
follow
laiv
vaccin
moreov
signal
also
enrich
group
pneumococc
protein
pneumolysin
sens
possibl
increas
pneumococc
load
follow
laiv
vaccin
led
increas
pneumolysin
sens
olink
glycosyl
mucin
use
spn
carbohydr
sourc
growth
also
enrich
laiv
carriag
group
includ
gene
sialyl
transferas
cleavag
sialic
acid
influenza
neuraminidas
previous
shown
promot
pneumococc
growth
find
support
laivmedi
effect
pneumococc
growth
alter
host
factor
common
gene
pathway
laivvaccin
control
carrier
includ
innat
immun
system
signal
interleukin
conclus
genomewid
transcriptom
respons
pneumococc
carriag
substanti
alter
gene
pathway
level
laiv
identifi
set
coexpress
gene
post
laiv
carriag
use
cemitool
baselinenorm
data
laiv
control
group
separ
modular
express
analysi
reveal
gene
may
act
togeth
similarli
regul
immun
respons
carriag
infect
gene
control
cohort
group
four
coexpress
modul
three
significantli
enrich
known
reactom
pathway
supplementari
inform
modul
enrich
carriag
day
post
spn
inocul
fig
number
monocyt
correl
averag
fold
chang
count
modul
suggest
gene
reflect
infiltr
monocyt
fig
investig
monocyt
perform
gene
set
enrich
analysi
modul
gene
use
list
gene
distinct
monocyt
subset
fig
gene
enrich
classic
monocyt
monocyt
subset
moreov
modul
enrich
gene
relat
chemokin
receptor
bind
chemokin
interferon
signal
fig
type
interferon
shown
requir
clearanc
pneumococc
carriag
murin
model
find
suggest
activ
monocyt
might
critic
cemitool
also
integr
coexpress
analysi
proteinprotein
interact
data
express
receptor
identifi
hub
modul
fig
supp
html
file
engag
shown
induc
attach
monocyt
endotheli
layer
initi
chemotaxi
suggest
interact
could
contribut
monocyt
recruit
modul
enrich
gene
relat
extracellular
matrix
organ
collagen
format
fig
laiv
identifi
six
distinct
coexpress
modul
supplementari
inform
strongli
enrich
gene
relat
diseas
associ
oglycosyl
protein
modul
immunoregulatori
interact
lymphoid
nonlymphoid
cell
modul
chemokin
receptor
bind
chemokin
modul
well
interferon
signal
modul
fig
inde
hub
modul
well
known
type
interferonrel
gene
oasl
altogeth
find
reveal
strong
local
antivir
respons
elicit
respons
laiv
infect
studi
address
fundament
question
immun
respons
control
clear
spn
carriag
influenza
infect
alter
control
use
first
time
doubl
experiment
human
challeng
model
laiv
spn
reveal
spn
carriag
led
quick
degranul
preexist
nasal
neutrophil
human
nose
recruit
monocyt
promot
bacteri
clearanc
laiv
infect
impair
immun
respons
follow
carriag
laiv
attenu
influenza
strain
wildtyp
influenza
virus
might
even
pronounc
effect
host
respons
pneumococcu
carriag
absenc
laiv
associ
limit
inflamm
corrobor
view
spn
commens
bacterium
asymptomat
colon
healthi
adult
contrast
robust
proinflammatori
cytokin
respons
measur
follow
laiv
protein
gene
express
level
altogeth
result
provid
explan
previou
report
laiv
increas
acquisit
spn
carriag
load
addit
find
laiv
led
impair
blood
neutrophil
kill
capac
addit
tnf
increas
follow
laiv
neutrophil
vitro
impair
activ
highlight
crucial
role
suscept
secondari
bacteri
infect
associ
tigit
impair
neutrophil
function
follow
influenza
infect
warrant
investig
tigitblock
therapeut
current
develop
cancer
hiv
treatment
identifi
marker
increas
suscept
spn
propos
investig
potenti
therapeut
target
secondari
bacteri
infect
associ
viru
infect
data
show
individu
higher
concentr
prior
spn
inocul
higher
bacteri
load
previou
studi
children
pneumonia
viral
bacteri
predominantli
pneumococc
coinfect
increas
amount
compar
children
viral
bacteri
pneumonia
associ
diseas
sever
murin
data
suggest
play
direct
role
pneumonia
mice
genet
ablat
receptor
show
increas
surviv
decreas
lung
inflamm
less
invas
follow
infect
depend
pneumococc
inocul
strain
use
moreov
addit
exogen
prior
infect
mice
influenza
respiratori
syncyti
viru
rsv
increas
pneumonia
sever
result
support
previou
find
murin
model
show
signal
monocyt
recruit
key
mediat
pneumococc
carriag
clearanc
howev
contrari
key
mechan
describ
murin
model
observ
product
neutrophil
recruit
nose
follow
carriag
associ
carriag
clearanc
underlin
import
confirm
murin
find
human
data
one
limit
studi
one
pneumococc
serotyp
isol
use
futur
studi
use
isol
less
invas
phenotyp
abl
answer
generaliz
find
across
pneumococc
isol
nonetheless
observ
carriag
load
durat
declin
parallel
serotyp
follow
repeat
exposur
suggest
immunolog
control
newlyacquir
spn
mediat
similar
mechan
independ
colon
serotyp
conclus
studi
highlight
import
innat
immun
control
carriag
load
clearanc
spn
impair
preexist
viral
infect
secondari
bacteri
infect
follow
viral
respiratori
tract
infect
larg
burden
diseas
worldwid
disrupt
viralbacteri
synergi
hostdirect
therapi
could
prove
attract
addit
current
therapeut
vaccin
option
healthi
adult
volunt
random
receiv
either
intranas
laiv
fluenz
tetra
flumist
tetra
astrazeneca
uk
intramuscular
quadrival
inactiv
influenza
vaccin
fluarix
tetra
glaxosmithklin
uk
describ
previous
control
group
also
receiv
nasal
salin
spray
laiv
group
also
receiv
intramuscular
salin
inject
three
day
post
vaccin
subject
inocul
cfu
per
nostril
type
spn
describ
nasal
microbiopsi
asl
arlington
scientif
nasal
line
fluid
hunt
develop
sampl
collect
store
previous
describ
doubleblind
random
clinic
laivehpc
trial
regist
eudract
number
april
isrctn
number
sep
cosponsor
royal
liverpool
univers
hospit
liverpool
school
tropic
medicin
key
elig
criteria
includ
capac
give
inform
consent
immunocompromis
state
contact
suscept
individu
pneumococc
influenza
vaccin
infect
last
two
year
taken
part
ehpc
studi
past
three
year
primari
endpoint
occurr
pneumococc
colonis
determin
presenc
pneumococcu
nasal
wash
sampl
nw
time
point
post
inocul
includ
day
detect
use
classic
microbiolog
lyta
qpcr
describ
studi
volunt
inocul
pneumococcu
give
power
identifi
increas
carriag
acquisit
vaccin
volunt
five
natur
pneumococc
carrier
two
laiv
arm
three
control
arm
exclud
analysi
anoth
subject
laiv
arm
exclud
follow
systemat
laiv
dispens
error
singl
practition
recommend
trial
steer
group
result
final
subject
analys
laiv
arm
subject
control
arm
key
secondari
endpoint
includ
load
pneumococc
colonis
nw
time
point
follow
pneumococc
inocul
day
detect
use
classic
microbiolog
area
curv
pneumococc
colonis
load
follow
pneumococc
inocul
day
detect
use
classic
microbiolog
molecular
method
lyta
immunolog
mechan
associ
alter
suscept
pneumococcu
follow
laiv
outcom
report
manuscript
priori
includ
studi
protocol
volunt
gave
written
inform
consent
research
conduct
complianc
relev
ethic
regul
ethic
approv
given
east
liverpool
nh
research
ethic
committe
rec
liverpool
school
tropic
medicin
lstm
rec
refer
number
human
tissu
author
licens
number
immunophenotyp
nasal
cell
obtain
curett
perform
describ
brief
cell
dislodg
curett
stain
fixabl
violet
dead
cell
stain
thermofish
antibodi
cocktail
contain
epcamp
biolegend
bd
bioscienc
thermofish
whole
blood
stain
min
room
temperatur
biolegend
follow
min
incub
step
facslysi
buffer
bd
bioscienc
remov
erythrocyt
sampl
acquir
lsrii
flow
cytomet
bd
analys
use
flowjo
x
treestar
fluoresc
minu
one
control
includ
antibodi
use
valid
result
laiv
control
cohort
addit
valid
cohort
supplementari
fig
sampl
less
immun
cell
epitheli
cell
exclud
analysi
neutrophil
kill
capac
evalu
previous
describ
minor
modif
briefli
neutrophil
isol
densiti
gradient
centrifug
follow
min
incub
serotyp
pneumococci
inocul
strain
moi
babi
rabbit
complement
mast
group
bootl
uk
human
intraven
immunoglobulin
ivig
gamunex
grifol
inc
spain
experi
recombin
tnf
biotechn
ad
nasal
cell
collect
rpmi
contain
penicillinstreptomycinneomycin
thermofish
heatinactiv
fb
thermofish
incub
dnase
sigma
aldrich
room
temperatur
min
filter
filter
thermofish
cell
spun
min
resuspend
count
incub
cellsml
plate
thermofish
heatkil
spn
inocul
strain
ad
concentr
total
protein
correspond
cfuml
cell
incub
h
bacteri
protein
concentr
measur
bradford
assay
use
bovin
serum
albumin
standard
titrat
experi
perform
determin
dose
supernat
collect
store
analysi
nasosorpt
filter
cytokin
elut
store
filter
use
ul
assay
buffer
thermofish
centrifug
eluat
clear
centrifug
prior
analysi
sampl
centrifug
min
clear
sampl
acquir
use
magnet
human
luminex
cytokin
kit
thermofish
analys
softwar
follow
manufactur
instruct
sampl
analys
duplic
nasosorpt
sampl
cv
exclud
nasal
cell
collect
rnalat
thermofish
extract
extract
perform
use
rneasi
micro
kit
qiagen
column
dna
digest
extract
rna
quantifi
use
thermofish
sampl
integr
assess
bioanalyz
agil
librari
prepar
rnasequenc
illumina
read
pairedend
read
perform
beij
genom
institut
china
purifi
blood
neutrophil
store
rlt
buffer
qiagen
sigma
rna
extract
singl
cell
immunolog
kit
nanostr
use
preamp
cycl
sampl
hybrid
sampl
prepar
prep
station
scan
max
nanostr
raw
count
analys
use
use
intern
normal
gave
lower
varianc
normal
includ
housekeep
gene
deg
identifi
use
model
matrix
correct
repeat
individu
measur
qualiti
control
raw
sequenc
data
done
use
fastqc
map
human
refer
genom
assembl
done
use
star
read
count
result
bam
align
file
obtain
featurecount
use
gtf
gene
annot
ensembl
databas
rbioconductor
packag
use
identifi
differenti
express
gene
among
sampl
remov
absent
featur
zero
count
sampl
gene
fdr
valu
absolut
fold
chang
fc
identifi
differenti
express
coexpress
analysi
count
normal
use
log
cpm
fold
chang
calcul
time
point
subjectwis
manner
coexpress
analysi
perform
separ
group
control
laiv
use
cemitool
packag
develop
group
avail
bioconductor
http
bioconductororgpackagesreleasebiochtmlcemitoolhtml
packag
unifi
discoveri
analysi
coexpress
gene
modul
evalu
modul
contain
gene
overrepres
specif
pathway
alter
specif
sampl
group
pvalu
appli
filter
lowli
express
gene
experi
perform
randomis
blind
twotail
statist
test
use
throughout
studi
lognorm
data
normal
distribut
nonparametr
test
perform
multipl
correct
test
benjaminhochberg
appli
gene
express
luminex
analysi
raw
rnasequenc
data
deposit
geo
repositori
access
number
underli
data
provid
manuscript
